Compare Lennar Corporation (LEN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs Novo Nordisk A/S — how do they compare? Lennar Corporation trades at $87.46 (market cap $21.05B), while Novo Nordisk A/S trades at $45.92 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 9.9× Lennar Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| LEN | NVO | |
|---|---|---|
Market Cap | $21.05B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $63.98 |
52-Week Low | $81.84 | $35.29 |
Enterprise Value | $24.93B | $222.55B |
Dividend Yield | 2.28% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
